Monday, December 22, 2014

Ciclofilin developing first drug for HCV/HIV-1 co-infection

Ciclofilin developing first drug for HCV/HIV-1 co-infection

June 24, 2014 by · Leave a Comment 

Tweet Closely held Ciclofilin Pharmaceuticals is developing what, it hopes, will be the first clinically effective treatment for hepatitis C virus (HCV)/HIV-1 co-infection, with specific antiviral activity directed against both viruses. “Other companies are working on one or the other virus, so we would like to position ourselves as the company working on co-infection, where […]

Isotechnika gets more funding for NICAM program

Isotechnika gets more funding for NICAM program

June 18, 2013 by · Leave a Comment 

Tweet Isotechnika Pharma (TSX: ISA) has received additional funding from the National Research Council Industrial Research Assistance Program (NRC-IRAP) for its non-immunosuppressive cyclophilin antagonist molecules (NICAM) program. NRC-IRAP continues to play an instrumental role in networking the NICAM program with key global partners and previously assisted Isotechnika in late-stage screening of several NICAM compounds, including […]

ILJIN withdraws damage claims against Isotechnika

ILJIN withdraws damage claims against Isotechnika

January 15, 2013 by · Leave a Comment 

Tweet Isotechnika Pharma (TSX:ISA) announced that ILJIN Life Sciences of South Korea has formally notified Isotechnika and the arbitral tribunal that it has withdrawn all claims for damages in the parties’ pending arbitration arising from a development, distribution and license agreement. As previously reported, the agreement was declared to be in “full force and effect” […]

Isotechnika’s NICAMs effective against Hepatitis C virus

Isotechnika’s NICAMs effective against Hepatitis C virus

December 6, 2012 by · Leave a Comment 

Tweet Isotechnika Pharma (TSX:ISA) has announced positive anti-hepatitis C virus (HCV) results from the second round of in vitro testing of its cyclophilin antagonist molecules (NICAMs) carried out by the NIH’s National Institute of Allergy and Infectious Diseases. Several NICAM compounds were tested for cross genotype activity using quantitative polymerase chain reaction in HCV replicons, […]

Isotechnika receives partial award in ICC arbitration

Isotechnika receives partial award in ICC arbitration

November 30, 2012 by · Leave a Comment 

Tweet Isotechnika Pharma (TSX:ISA) has received a partial award from the International Chamber of Commerce Court of Arbitration regarding its right to terminate a development, distribution and license (DDL) agreement with ILJIN Life Sciences of South Korea. The partial award provides that the DDL has not been terminated and the company’s contractual relationship with ILJIN […]

Isotechnika highlights upcoming milestones in Q3 report

Isotechnika highlights upcoming milestones in Q3 report

November 14, 2012 by · Leave a Comment 

Tweet Isotechnika Pharma (TSX:ISA) expects a decision shortly from the International Chamber of Commerce (ICC) Court of Arbitration on its right to terminate a development, distribution and license agreement with ILJIN Life Science Co. Isotechnika made the disclosure in its third quarter report. It terminated the accord with ILJIN last January. In addition, Isotechnika partner […]

Isotechnika’s NICAMs demonstrate anti-viral activity

Isotechnika’s NICAMs demonstrate anti-viral activity

November 6, 2012 by · Leave a Comment 

Tweet Isotechnika Pharma (TSX: ISA) announced positive results from the first round of screening of its portfolio of cyclophilin antagonist molecules (NICAMs) through the contract testing laboratories of the National Institute of Allergy and Infectious Disease, which is part of the NIH. NICAMs are an emerging novel class of multifunctional drugs showing promise as antiviral, […]

Isotechnika arranges private placement

Isotechnika arranges private placement

October 16, 2012 by · Leave a Comment 

Tweet Isotechnika Pharma (TSX:ISA) intends to complete a non-brokered private placement of up to 21.25 million units at a price of four cents a unit for total gross proceeds of $850,000. Each unit will consist of one common share and one warrant exercisable at five cents for a period of two years from closing. Proceeds […]

Isotechnika gets added Canadian funding for NICAMs

Isotechnika gets added Canadian funding for NICAMs

July 17, 2012 by · Leave a Comment 

Tweet Isotechnika Pharma (TSX:ISA) has received approval for additional funding from the National Research Council Industrial Research Assistance Program (NRC-IRAP) for its Non-Immunosuppressive Cyclosporin Analog Molecules (NICAM) program. NRC-IRAP previously assisted Isotechnika in the discovery of a series of NICAMs that were shown to be potent inhibitors of a class of proteins called cyclophilins. Research […]

Isotechnika partner completes enrolment in Phase 3 uveitis study

Isotechnika partner completes enrolment in Phase 3 uveitis study

July 9, 2012 by · Leave a Comment 

Tweet Isotechnika Pharma (TSX:ISA) partner, Lux Biosciences, has completed patient enrolment in its Phase 3 clinical study using voclosporin (branded as Luveniq) for the treatment of non-infectious uveitis, a leading cause of vision loss and long-term disability. Lux anticipates that data from the Phase 3 study will be available early in the first quarter of […]

Next Page »

Email Newsletters with Constant Contact
Google+